MHMuhammad Hasnawi Haddani

Muhammad Hasnawi Haddani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Muhammad Hasnawi Haddani has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Effectiveness of Neurofeedback Training on Cognitive Function Improvement and Quantitative Electroencephalography Features in Poststroke Cognitive Impairment

    by Rini Nindela, Yohanes Febrianto, Yusril Yusril, Muhammad Hasnawi Haddani, Sri Handayani, Dya Anggraeni, Mgs. Irsan Saleh

    Background. Poststroke cognitive impairment (PSCI) involves cognitive deficits emerging within 3 months after stroke. Quantitative EEG (qEEG) in PSCI typically shows changes in relative power, delta-alpha ratio, and peak alpha frequency. Neurofeedback training (NFT) is a promising intervention to improve cognitive function and qEEG patterns, though findings remain inconsistent. Nonetheless, even brief NFT interventions may yield meaningful benefits. Methods. This study assessed the effectiveness of five individualized qEEG-guided NFT sessions (30 min each) in 24 PSCI patients, focusing on changes in MoCA-INA scores and qEEG parameters. Results. NFT significantly improved MoCA-INA scores (Z = −4.106, p < .001, effect size = 0.839), particularly in visuospatial/executive and delayed recall domains, with sustained effects 1 month later. QEEG analysis revealed increased temporal alpha (t = −1.875, p = .037, effect size = 0.23) and parietal beta relative power (t = −1.827, p = .040, effect size = 0.11). Greater cognitive gains were observed in patients aged ≤60 years. Conclusion. These findings support the clinical utility of short-term, qEEG-guided NFT in improving cognitive outcomes and modulating neural activity in PSCI patients. The sustained benefits observed suggest potential for long-term therapeutic impact.

  • Open Access

    Management of peripheral neuropathy symptoms with a fixed dose combination of high-dose vitamin B1, B6 and B12: A 12-week prospective non-interventional study in Indonesia

    by Manfaluthy Hakim, Nani Kurniani, Rizaldy Taslim Pinzon, Dodik Tugasworo, Mudjiani Basuki, Hasmawi Haddani, Pagan Pambudi, Aida Fithrie, Audry Devisanty Wuysang

    Background: Peripheral neuropathy is a common condition which can have a significant impact on quality of life. It occurs as a component of several common and rare diseases or can be idiopathic and can present with various symptoms.Aims and Objectives: This study is aimed at evaluating the effectiveness and safety of the fixed dose combination of vitamin B1, B6 and B12in mild to moderate peripheral neuropathy of various etiologies in the Indonesian population.Materials and Methods: This was a prospective, open label, multi-center, single arm observational study (Indonesian Clinical Trial Registry No: INA-KPA0DYA). A total of 411 subjects with mild to moderate peripheral neuropathy of various etiologies, who met the eligibility criteria, were included in the study. A subject was considered to have “completed” the study if the study procedures, up to Visit 3 (one month of treatment) were accomplished. Procedural results and 12-week clinical outcomes are reported.Results: Treatment with combination of vitamin B1, B6 and B12 in subjects with symptoms of PN showed significant improvement in overall Total Symptom Score (TSS), within 14 days. The treatment also successfully reduced individual components of TSS from baseline to Visit 5. A significant percentage reduction was also observed for all the Visual Analogue Scale (VAS) parameters at the end of 12 weeks, while the Quality of Life (QoL) scores increased from baseline to the end of treatment.Conclusions: The fixed dose combination of vitamin B1, B6 and B12 was effective and welltolerated in subjects with mild to moderate peripheral neuropathy, of various etiologies.Asian Journal of Medical Sciences Vol.9(1) 2018 32-40